Paul Matteis
Stock Analyst at Stifel
(2.33)
# 2,629
Out of 5,182 analysts
131
Total ratings
43.18%
Success rate
-0.05%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $21.27 | +41.04% | 1 | Apr 17, 2026 | |
| IMUX Immunic | Initiates: Buy | $25 | $10.75 | +132.56% | 1 | Apr 17, 2026 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $35 → $40 | $31.38 | +27.47% | 3 | Mar 27, 2026 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $39 → $42 | $19.24 | +118.30% | 2 | Mar 26, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $71.78 | +7.27% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $22.67 | +5.87% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $430.14 | +8.34% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $18.05 | +121.61% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $128.12 | +46.74% | 11 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $18.16 | +114.76% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $495 → $508 | $302.11 | +68.15% | 16 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $30.31 | -7.62% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $3 | $2.25 | +33.33% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $53.30 | +14.45% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $183.38 | +10.15% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $1.58 | +659.49% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $84.18 | +11.67% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $39.59 | -19.17% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $19.85 | +61.21% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $8.44 | +30.33% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.39 | +67.36% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $24.47 | -59.13% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $27.45 | +118.58% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $34.14 | +5.45% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $33.74 | +3.73% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.52 | +131.72% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.81 | +244.23% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.60 | +1,911.40% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $2.46 | +997.56% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $7.52 | +751.06% | 1 | Feb 21, 2018 |
Definium Therapeutics
Apr 17, 2026
Initiates: Buy
Price Target: $30
Current: $21.27
Upside: +41.04%
Immunic
Apr 17, 2026
Initiates: Buy
Price Target: $25
Current: $10.75
Upside: +132.56%
LB Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $31.38
Upside: +27.47%
KalVista Pharmaceuticals
Mar 26, 2026
Maintains: Buy
Price Target: $39 → $42
Current: $19.24
Upside: +118.30%
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $71.78
Upside: +7.27%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $22.67
Upside: +5.87%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $430.14
Upside: +8.34%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $18.05
Upside: +121.61%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $128.12
Upside: +46.74%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $18.16
Upside: +114.76%
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $302.11
Upside: +68.15%
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $30.31
Upside: -7.62%
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $2.25
Upside: +33.33%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $53.30
Upside: +14.45%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $183.38
Upside: +10.15%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $1.58
Upside: +659.49%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $84.18
Upside: +11.67%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $39.59
Upside: -19.17%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $19.85
Upside: +61.21%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $8.44
Upside: +30.33%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.39
Upside: +67.36%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $24.47
Upside: -59.13%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $27.45
Upside: +118.58%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $34.14
Upside: +5.45%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $33.74
Upside: +3.73%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $12.52
Upside: +131.72%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $5.81
Upside: +244.23%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.60
Upside: +1,911.40%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $2.46
Upside: +997.56%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $7.52
Upside: +751.06%